Contraindications for Drug-Resistant Tuberculosis Medications
Bedaquiline
Bedaquiline has no absolute contraindications listed in FDA labeling, but carries a black box warning for increased mortality and QT prolongation that requires careful patient selection and monitoring. 1
Key Precautions (Not Absolute Contraindications):
- Severe hepatic impairment (Child-Pugh C) should be avoided, though mild to moderate hepatic impairment (Child-Pugh A or B) is acceptable with close monitoring 1
- Severe renal impairment requiring dialysis warrants cautious use with consideration of serum drug level monitoring 1
- Pre-existing cardiac conditions require intensive monitoring but are not absolute contraindications:
- History of torsade de pointes
- Congenital long QT syndrome
- Hypothyroidism with bradyarrhythmias
- Uncompensated heart failure 1
Critical Monitoring Requirements:
- Discontinue bedaquiline if QTcF >500 ms (confirmed by repeat ECG) or clinically significant ventricular arrhythmia develops 1
- Discontinue if aminotransferases >8× ULN or aminotransferases accompanied by total bilirubin >2× ULN 1
- Avoid concurrent use with rifamycins or other CYP3A4 inducers/suppressors unless benefits outweigh risks 1
Common Pitfall:
The long terminal half-life (4-5 months) means bedaquiline should be discontinued 4-5 months before other drugs in the regimen to prevent functional monotherapy and acquired resistance 1
Linezolid
Linezolid has no specific absolute contraindications listed in standard references for DRTB use, but dose and duration modifications are essential to minimize toxicity while maintaining efficacy. 2
Evidence-Based Dosing to Minimize Toxicity:
- Optimal regimen: 600 mg daily for 26 weeks when combined with bedaquiline and pretomanid, providing the best risk-benefit ratio with 91% favorable outcomes 2
- Higher doses (1200 mg daily) associated with significantly increased toxicity:
- Peripheral neuropathy: 38% vs 13% (1200 mg vs 600 mg for 26 weeks)
- Myelosuppression: 22% vs 2%
- Optic neuropathy: 9% (only in 1200 mg group) 2
Key Monitoring Requirements:
- Peripheral neuropathy occurs in 13-38% depending on dose and requires dose modification 2, 3
- Myelosuppression necessitates regular complete blood count monitoring 2
- Optic neuropathy can occur but typically resolves after discontinuation 2
Common Pitfall:
Shorter duration (9 weeks) of linezolid associated with higher microbiologic failure rates; 26-week duration is preferred 2
Levofloxacin
Levofloxacin is contraindicated in persons with known hypersensitivity to levofloxacin or other quinolone antibacterials. 4
Additional Considerations:
- Fluoroquinolone resistance is a critical concern in DRTB; susceptibility testing should ideally be performed before treatment initiation 5
- Risk of QT prolongation when combined with bedaquiline and clofazimine requires weekly ECG monitoring 1
- Part of the strongly recommended core regimen (bedaquiline, levofloxacin/moxifloxacin, linezolid) for MDR/RR-TB 1
Common Pitfall:
Undetected fluoroquinolone resistance increases risk of acquired bedaquiline resistance, making drug susceptibility testing essential before treatment 5
Cefazolin
Cefazolin is contraindicated in patients with known allergy to the cephalosporin group of antibiotics. 6
Important Context:
- Cefazolin itself is not a standard DRTB medication
- Carbapenems with clavulanic acid (not cefazolin) are used for MDR and XDR-TB, showing in vitro bactericidal activity 1
- The carbapenem regimen requires concurrent amoxicillin-clavulanate since clavulanate is not available alone 1
Cycloserine
Cycloserine is contraindicated in patients with:
- Hypersensitivity to cycloserine
- Epilepsy
- Depression, severe anxiety, or psychosis
- Severe renal insufficiency
- Excessive concurrent use of alcohol 7
Clinical Significance:
- Central nervous system toxicity is the primary concern, including psychiatric manifestations and seizures 3
- Part of the WHO-recommended supplemental drugs (cycloserine and/or clofazimine) added to the core bedaquiline-fluoroquinolone-linezolid regimen 5
- Combination with linezolid increases risk of neurologic adverse effects requiring careful monitoring 3
Common Pitfall:
Baseline psychiatric evaluation is essential before initiating cycloserine, as pre-existing mental health conditions significantly increase risk of severe CNS adverse effects 7, 3